

RULE 63 (37 CFR § 1.63)
DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "NOVEL PARASITE ASTACIN METALLOENDOPEPTIDASE PROTEINS," the specification of which has been prepared and filed on January 6, 1998, receiving Serial No. 09/003,574, and further identified as Attorney File No. 2618-21-1-C1.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability in accordance with 37 CFR 1.56(a) and (b) as set forth on the attached sheet indicated Page 3 hereof and which I have read.

I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)		Priority Claimed
<u>Number</u>	<u>Country</u>	<u>Yes</u> <u>No</u>

I hereby claim the benefit under 35 U.S.C. 120/365 of all United States and PCT international applications listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information material to patentability in accordance with 37 CFR 1.56(a) and (b) which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
08/463,994	6/5/95	abandoned
08/249,552	5/26/94	abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



(1)

Inventor's Signature

Cynthia Ann Tripp

Date

4-24-98

Inventor's Name (typed):

Cynthia Ann Tripp

Citizenship:

USA

Residence:

2934 Zendt Drive

Ft. Collins, Colorado 80526

Post Office Address*:

Same as Residence

(2)

Inventor's Signature

Glenn Robert Frank

Date

24 Apr 98

Inventor's Name (typed):

Glenn Robert Frank

Citizenship:

USA

Residence:

10317 North County Road 13

Wellington, Colorado 80549

Post Office Address*:

Same as Residence

RECEIVED

MAY 13 1998

U.S. PATENT & TRADEMARK OFFICE
WASHINGTON, D.C. 20540

(3)

Inventor's Signature

Robert B. Grieve

Date

4/24/98

Inventor's Name (typed):

Robert B. Grieve

Citizenship:

USA

Residence:

38501 Weld County Road 21

Fort Collins, Colorado 80524

Post Office Address*:

Same as Residence

*Complete Post Office Address in full if different from Residence, otherwise indicate that the Post Office Address is "Same as Residence."

POWER OF ATTORNEY

On behalf of Heska Corporation, a Delaware corporation having a principal place of business at 1825 Sharp Point Drive, Ft. Collins, CO 80525 being the assignee of and owning all right, title and interest in the invention entitled "NOVEL PARASITE ASTACIN METALLOENDOPEPTIDASE PROTEINS," for which application for Letters Patent of the United States has been made by Cynthia Ann Tripp, Glenn Robert Frank and Robert B. Grieve, said application having been filed on January 6, 1998, receiving Serial No. 09/003,574, and further identified as Attorney File No. 2618-21-1-C1, I, John A. Shadduck, DVM, PhD, Executive Vice President, Operations, hereby appoint David F. Zinger, Registration No. 29,127; Craig C. Groseth, Registration No. 31,713; Michael L. Tompkins, Registration No. 30,980; Sabrina C. Stavish, Registration No. 33,374; Todd P. Blakely, Registration No. 31,328; Lewis D. Hansen, Registration No. 35,536; Joseph E. Kovarik, Registration No. 33,005; Gary J. Connell, Registration No. 32,020; Wannell M. Crook, Registration No. 31,071; Douglas W. Swartz, Registration No. 37,739; John C. Scott, Registration No. 38,613; Bruce A. Kugler, Registration No. 38,942; Robert R. Brunelli, Registration No. 39,617; Chester E. Martine, Jr., Registration No. 19,711; Richard L. Hughes, Registration No. 31,264; Tejpal S. Hansra, Registration No. 38,172; Dana L. Hartje, Registration No. 40,638; Don D. Cha, Registration No. 40,945; Angela Dallas-Pedretti, Registration No. P-42,460; and Benjamin B. Lieb, Registration No. P-42,801, of SHERIDAN ROSS P.C., 1700 Lincoln Street, Suite 3500, Denver, Colorado 80203, telephone number (303) 863-9700, as attorneys and agents for Paravax, Inc. with full powers of substitution, association and revocation to prosecute the application and related U.S. and foreign applications and to transact all business in the United States Patent and Trademark Office and all foreign and international patent offices connected therewith.

Date: April 24, 1998

By: John A. Shadduck
Name: John A. Shadduck, DVM, PhD
Title: Executive Vice President, Operations